Novartis Marks 20 Years of Improving Patients' Lives With Innovative Treatments for Transplantation

BN003644 14 de maio de 2004 09:07 HORALOCAL

CIÊNCIA

Novartis Marks 20 Years of Improving Patients' Lives With Innovative Treatments for Transplantation

Past, Present and Future Products Span All Therapeutic Classes to Address Major Unmet Medical Needs

BASEL, Switzerland, May 14 /PRNewswire/ -- Demonstrating the strength of its 20 year commitment to improving transplant patients' lives, Novartis will present more than 50 abstracts on existing products and developmental compounds at the fifth annual American Transplant Congress (ATC) next week in Boston. The data presented provide new insights into Novartis Transplantation's research strategies and the potential of Novartis' products to enhance therapeutic choices for transplant physicians and patients.

"Our goal is to provide treatment options that meet the needs of individual patients - resulting in more successful transplants, better outcomes, safer therapies and longer, healthier lives for the transplant patients," said Tony Rosenberg, Head, Transplantation and Immunology Business Unit, Novartis Pharma AG. "For the transplant patient, it is no longer just a question of life, it is a question of living." Novartis helped revolutionize the transplant field two decades ago by introducing Sandimmune(R) (cyclosporin). Novartis now provides physicians and patients with the largest selection of innovative transplant therapies of any pharmaceutical company, including the world's most widely prescribed anti-rejection product, Neoral(R) (cyclosporin for microemulsion), the recently approved myfortic(R) (enteric coated mycophenolate sodium) film tablets and Certican(R) (everolimus) which received European Mutual Recognition in 15 countries in December 2003.

"The introduction of cyclosporin 20 years ago revolutionized transplant patients' survival," said Russell H. Wiesner, M.D., President, United Network for Organ Sharing (UNOS). "As a result, many more people with organ failure became viable candidates for transplantation and there has been a dramatic increase in the number of organ transplants performed annually worldwide over the last two decades."

Today there are currently around 460,000 de novo and maintenance transplant patients alive worldwide. Novartis has continued to fuel advances in the science of transplantation with the introduction of a range of products including Simulect(R) (basiliximab). Although transplantation has achieved great successes over the past 20 years, there are still advances that can be made to improve patients' quality of life. Novartis' aim is to enhance transplant patients' therapy with the introduction of innovative therapies. "Every day I am both amazed and thankful for Novartis' ongoing research and introduction of new treatments that continue to improve the lives of transplant recipients," said Meghan Kelly, mother and living donor of liver transplant recipient, Thomas Kelly. "It has been nearly five years since my son's transplant surgery and thanks to novel therapies, not only does Thomas now live a normal life for a six year old, but sometimes, I almost forget that he needs to be taking medicine daily."

The Novartis Transplantation and Immunology Team is committed to developing a new and innovative range of therapeutic products for the prophylaxis of organ rejection in order to provide the most extensive choice of drugs to the transplant community and to maintain Novartis' role as a global market leader in this field of medicine.

This release contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "will present", "potential...to enhance", "provide treatment options", "committed to developing", "to maintain", or similar expressions, or by express or implied discussions regarding the potential development and commercialization of new products or regarding potential future sales from any such products. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Any such commercialization or sales can be affected by, among other things, uncertainties relating to product development and clinical trials, regulatory actions or delays or government regulation generally, the ability to obtain or maintain patent or other proprietary intellectual property protection and competition in general, as well as factors discussed in the Company's Form 20-F filed with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. The Company is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Novartis AG (NYSE: NVS) is a world leader in pharmaceuticals and consumer health. In 2003, the Group's business achieved sales of USD 24.9 billion and a net income of USD 5.0 billion. The Group invested approximately USD 3.8 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ about 78, 500 people and operate in over 140 countries around the world. For further information please consult http://www.novartis.com .

Nadine Schecker

Novartis Global Communications

Tel + 41 61 324 2710

Fax + 41 61 324 3300

nadine.schecker@group.novartis.com

Eric Althoff

Novartis Pharma Communications

Tel + 41 61 324 6392

Fax + 41 61 324 2224

eric.althoff@pharma.novartis.com

FONTE Novartis AG
14/05/2004
CONTATO: Nadine Schecker of Novartis Global
Communications, +41-61-324-2710, or fax +41-61-324-3300, or
nadine.schecker@group.novartis.com, or Eric Althoff of
Novartis Pharma Communications, +41-61-324-6392, or fax,
+41-61-324-2224, or eric.althoff@pharma.novartis.com
First Call Analyst:
FCMN Contact: nadine.schecker@group.novartis.com
Web site: http://www.pharma.novartis.com
(NVS)


BNED: NG

FONTE: PR NEWSWIRE LATIN AMERICA
CORAL GABLES - MIAMI-US
CONTATOS: USA-MARY D'LEON
BRASIL-NÉLIA GARCIA
TELS: USA:1-305-507-2550/BRASIL:55-21-2132-8461
FAXES: USA:1-305-461-8670/BRASIL:55-21-2132-8469
E-MAILS: nelia_garcia@prnewswire.com.br mary_dleon@prnewswire.com

PALAVRA-CHAVE: RJ
PALAVRA-CHAVE/RAMO DE ATIVIDADE: INDÚSTRIA FARMACÊUTICA
PALAVRA-CHAVE/EMPRESA: NOVARTIS AG

======================================================================
O texto acima, distribuído pela PR Newswire Brasil, é de inteira
responsabilidade de seu cliente. A utilização deste material não
implica em custo.
======================================================================